Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sichuan University
With
Chengdu MedGenCell, Co., Ltd.
This is a dose-escalation study of ex-vivo knocked-out, expanded, and selected PD-1 knockout-T cells from autologous origin. Patients are assigned to 1 of 3 treatment groups to determine the maximal tolerant dose. After the lower number of cycles are considered tolerant, an arm of the next higher number of cycles will be open to next patients. Biomarkers and immunological markers are collected and analyzed as well.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically verified stage IV non-small cell lung cancer with measurable lesions (On CT: longest diameter of tumoral lesion \>=10 mm, shorted diameter of lymph node \>=15 mm; measurable lesions should not have been irradiated)
Progressed after all standard treatment
Performance score: 0-1
Expected life span: \>= 6 months
Toxicities from prior treatment has resolved. Washout period is 4 weeks for chemotherapy, and 2 weeks for targeted therapy
Major organs function normally
Women at pregnant ages should be under contraception
Willing and able to provide informed consent
You may not be if
Pathology is mixed type
Emergent treatment of tumor emergency is needed
Poor vasculature
Coagulopathy, or ongoing thrombolytics and/or anticoagulation
Blood-borne infectious disease, e.g. hepatitis B
History of mandatory custody because of psychosis or other psychological disease inappropriate for treatment deemed by treating physician
With other immune diseases, or chronic use of immunosuppressants or steroids
Compliance cannot be expected
Other conditions requiring exclusion deemed by physician